Održavatelji se pripremaju za smanjenje plaće, i možda beskućnike

Across the United States, caregivers, many of whom are parents, face the prospect of severe financial strain as state governments prepare to cut funding for programs supporting individuals with intellectual and developmental disabilities. These reductions, driven by provisions in the Republican-led One Big Beautiful Bill Act, aim to reduce federal spending on Medicaid by approximately $1 trillion over the next decade. The impact is being felt most acutely by families who rely on state-funded support to care for loved ones with complex medical needs, leaving some at risk of losing their homes or facing homelessness. In several states, including Florida, Texas, and Georgia, lawmakers are considering or have already implemented measures to reduce payments made to caregivers. These funds are critical for covering expenses related to personal care, therapy, and other essential services. For many families, the loss of this income represents a lifeline that, once removed, leaves them unable to afford basic living costs. Some caregivers have been forced to choose between providing necessary care for their children and maintaining stable employment, further compounding their financial instability. Two mothers in particular have drawn attention to the crisis. Both are raising children with severe disabilities whose care demands extensive time and resources. Without additional support, they fear they will be unable to continue providing adequate care at home and may be forced to place their children in institutional settings. One woman described her dilemma as a choice between enduring the uncertainty of remaining in her home until she is evicted or seeking alternative arrangements for her son's care. Her emotional struggle highlights the broader implications of policy decisions that affect vulnerable populations. Meanwhile, in the field of oncology, a breakthrough in pancreatic cancer treatment has sparked both excitement and concern among medical professionals. A new drug called daraxonrasib, developed by Revolution Medicine, showed remarkable results in a recent clinical trial involving 500 participants. Those receiving the drug had nearly double the survival rate compared to patients undergoing traditional chemotherapy. Although the drug has not yet received regulatory approval, interest in its potential has grown rapidly, prompting discussions about how best to manage patient expectations and ensure equitable access. At a recent conference in London focused on pancreatic cancer, experts acknowledged the challenges that lie ahead. While the drug’s efficacy is promising, questions remain regarding its cost, availability, and possible side effects. Doctors anticipate that disparities in access could emerge quickly, especially given the high price tag associated with innovative treatments. Clinicians are preparing for difficult conversations with patients and families about the realities of limited access and the need for careful management of expectations. In another development, the U.S. Department of Health and Human Services is working on updated guidelines aimed at helping patients transition off antidepressant medications. This initiative follows criticism from HHS Secretary Robert F. Kennedy Jr., who has raised concerns about the overuse of selective serotonin reuptake inhibitors (SSRIs). The proposed guidance seeks to provide healthcare providers with practical tools and information to assist patients in safely discontinuing these medications. Many physicians expressed frustration over the lack of formal training on this topic, noting that it is rarely covered in medical education. As part of ongoing efforts to address public health preparedness, the Trump administration has nominated Sean Kaufman, co-founder of a consulting firm known for questioning vaccine safety, to serve as Assistant Secretary for Preparedness and Response within the Department of Health and Human Services. Kaufman’s appointment has raised eyebrows, particularly given his history of expressing doubts about the safety of vaccines. His views contrast sharply with the government’s emphasis on ensuring robust responses to health emergencies, which typically involve widespread vaccination campaigns. His inclusion in leadership roles signals a shift in priorities that could influence national approaches to public health crises.